**THE TIME TO ACTe IS NOW!**

Current medications prescribed for sarcoidosis were determined without adequate representation of Black Americans in clinical trials, despite their being **2.5x more likely** to have sarcoidosis than White Americans.

**ADVANCE CLINICAL TRIALS FOR EQUITY IN SARCOIDOSIS**

**TAKE THE FIRST STEP**

Complete FSR’s Patient Survey for Black Americans with sarcoidosis (Incentives provided) by visiting:

**STOPSARCOIDOSIS.ORG/ACTeNOW**

Increasing representation of Black Americans in clinical trials and research is the pathway to developing and identifying the most effective treatments and better health outcomes for Black patients with sarcoidosis.

**ACCORDING TO THE FDA,**

**Only 7% of clinical trial participants are Black**

Without proper representation of Black Americans in clinical trials, therapies may not account for greater health risks, comorbidities, and higher hospitalization and mortality rates.

**THERE ARE MORE SARCOIDOSIS CLINICAL TRIALS NOW THAN EVER, SO THE TIME TO ACTe IS NOW!**

**BENEFITS INCLUDE…**

- more frequent communication with providers
- increased access to medication, expert clinicians, and advanced technologies
- monitoring regardless of insurance status

**CLINICAL TRIALS & RESEARCH CAN BE AS SIMPLE AS…**

- surveys, patient registries, or interviews
- health education programs
- trying medications that have been FDA approved for safety in other diseases
- a simple blood draw
- trying new potential therapies with close oversight

**IGNORE NO MORE!**

Help improve care for yourself, family members impacted by sarcoidosis, and future generations! **Be part of the solution. ACTe Now. Learn How. Visit stopsarcoidosis.org/ACTeNOW**

Sponsored by Boehringer Ingelheim, Kinevant Sciences, and Mallinckrodt Pharmaceuticals and made possible in part by a grant from the Chan Zuckerberg Initiative. All sources available on the website.